ArticleFrontiers in oncology2026
Exploring the recurrence and metastasis of breast invasive ductal carcinoma based on machine learning and survival analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Invasive ductal carcinoma (IDC), the predominant histopathological subtype comprising about 80% of breast malignancies, continues to pose a significant clinical challenge due to frequent recurrence. Existing relapse prediction models remain limited in accuracy and generalizability. This study aimed to construct and validate machine learning-based models for predicting 5-year (short- to medium term) recurrence and metastasis risk in IDC, based on recurrence-free survival (RFS) analysis. Methods: A total of 640 IDC cases diagnosed between January 2017 and December 2019 were enrolled, data were partitioned into three sets: the training set (n = 303) from Fudan University Shanghai Cancer Center; the validation set (n = 217) from Shaoxing Central Hospital; and the test set (n = 120) from Zhejiang Cancer Hospital. Independent prognostic factors were identified through univariate and multivariate Cox regression analyses. Three predictive strategies were implemented: evaluating recurrence risk, distinguishing local from distant recurrence, and identifying metastatic sites. Light Gradient Boosting Machine (LGBM), XGBoost (XGB), Random Forest (RF), k-Nearest Neighbor (KNN), Neural Network (NN), and Support Vector Machine (SVM) were trained and validated. Results: The median follow-up duration was 5.7 years. Multivariate Cox regression analyses identified multiple factors significantly associated with RFS, including the rad-score, Ki-67 index, lymph node metastasis, tumor histological grade, and breast cancer family history in first- or second-degree relatives (all Conclusion: This study underscores the utility of machine learning models in forecasting recurrence and metastatic behavior in IDC. The clinical-radiomic nomograms proved valuable for individualized surgical and therapeutic decision-making in IDC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.